

Improvements of Dissolution Characteristics and Chemical Stability of 16,16-Dimethyl-*trans*- Δ^2 -prostaglandin E₁ Methyl Ester by Cyclodextrin Complexation

KANETO UEKAMA ^{*}, FUMITOSHI HIRAYAMA ^{*}, YOSHITSUGU YAMADA ^{*}, KOJI INABA [‡], and KEN IKEDA [§]

Received July 31, 1978, from the ^{*}Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 862, Japan, ¹Ono Pharmaceutical Co. Ltd., Osaka, 537, Japan, and the [§]Faculty of Pharmaceutical Sciences, Nagoya City University, Nagoya, 467, Japan. Accepted for publication February 6, 1979.

Abstract □ Inclusion complexation of 16,16-dimethyl-*trans*- Δ^2 -prostaglandin E₁ methyl ester (I), which is effective in early pregnancy termination, with cyclodextrins in water was ascertained by a solubility study. A solid complex of I- β -cyclodextrin in a 1:2 molar ratio was obtained, and its dissolution behavior and chemical stability were examined. The results indicated that the complex may have great utility as a rapidly dissolving form of I with prolonged storage time.

Keyphrases □ Prostaglandin E₁ derivatives—cyclodextrin complexation, dissolution, stability □ Cyclodextrin—complexation with prostaglandin E₁, dissolution, stability □ Complexation—prostaglandin E₁ with cyclodextrin, dissolution, stability

Some naturally occurring prostaglandins such as prostaglandins E₁, E₂, and F_{2 α} (dinoprost) have clinical applications (1). 16,16-Dimethyl-*trans*- Δ^2 -prostaglandin E₁ methyl ester¹ (I), a prostaglandin E₁ derivative, induced uterine contraction in rats with an efficacy 10 times that of prostaglandin F_{2 α} (2, 3). This compound is more acceptable for early pregnancy termination than prostaglandin F_{2 α} because it produces fewer side effects. However, the solubility and chemical instability of the prostaglandins, including I, in aqueous solution have limited dosage form development and resulted in a substantial challenge to the pharmaceutical scientist.

Cyclodextrins form inclusion complexes with various drug molecules (4–8). Since I is essentially a methyl ester of long chain unsaturated fatty acids, the relatively hydrophobic cyclodextrin cavity is expected to attract I as an adequate guest molecule (9–11). Thus, the present study dealt with inclusion complexation of I with α - and β -cyclodextrins in anticipation of improved solubilization and stabilization of I.

EXPERIMENTAL

Materials—Compound I¹, α -cyclodextrin², and β -cyclodextrin² were used as supplied. All other materials and solvents were analytical reagent grade. Deionized, double-distilled water was used.


Solubility and Dissolution Studies—Solubility measurement and analytical methods for I were essentially those reported previously (9).

Table I—Thermal Stabilities of I and Its β -Cyclodextrin Complex at 60°

Compound	Decomposition of I, %			
	1 Day	3 Days	8 Days	14 Days
I	2.2	8.8	30.2	54.0
Complex	0.1	0.5	2.5	4.0

¹ 9-Oxo-11 α ,15 α -dihydroxy-16,16-dimethyl-2-*trans*,13-*trans*-prostadienoic acid methyl ester (ONO-802). Supplied by Ono Pharmaceutical Co. Ltd., Osaka, Japan.

² Teijin Ltd., Tokyo, Japan.



The dissolution behaviors of I and its β -cyclodextrin complex in water were compared at the same I concentration according to the dispersed amount method (12). A 120-mg sample of a I- β -cyclodextrin complex as a 100–200-mesh powder was weighed and put in a dissolution cell. Because I is a viscous oil, an ether solution containing 18 mg of I was placed in the dissolution cell and evaporated to dryness. The dissolution medium (25 ml) was maintained at 25° and stirred at 93 rpm. At an appropriate interval, 0.5 ml of solution was sampled by a pipet with a cotton filter. The assay procedure for I was the same as that used in the solubility study (9).

Stability Studies—Stability tests for I and its β -cyclodextrin complex were conducted at 60° in a moisture-free environment. Intact I was quantitatively determined by high-performance liquid chromatography (HPLC). The liquid chromatograph³ (20-cm column⁴) was operated at a flow rate of 0.5 ml/min, and the mobile phase consisted of acetonitrile-methanol-water (2:8:3). Under these conditions, the disappearance of the I peak was followed by a UV detector⁵ at 215 nm.




Figure 1—Solubility of I as a function of cyclodextrin concentration in water at 25°. Key: ○, α -cyclodextrin; and ●, β -cyclodextrin.

³ Model FLC-A700, Jasco, Tokyo, Japan.

⁴ Packed with LiChrosorb RD-18, E. Merck, Darmstadt, West Germany.

⁵ Model UVDEC-1M, Jasco, Tokyo, Japan.




Figure 2—Dissolution behavior of I (○) and its β -cyclodextrin complex (●) at the same I concentration in water at 25°.

RESULTS AND DISCUSSION

The equilibrium phase solubility diagrams obtained for I with α - and β -cyclodextrins in water are shown in Fig. 1. In both of these systems, the solubility of I increased following cyclodextrin addition, and the solubility curves of α - and β -cyclodextrins can be generally classified as types A_p and B_s (13), respectively. According to Higuchi and Kristiansen (14), the stability constants for 1:1 (SL) and 1:2 (SL₂) complexes (S = I, and L = cyclodextrin) were calculated from ascending positive curvatures in Fig. 1. The stability constants for α - ($K_{1:1} = 820 M^{-1}$, and $K_{1:2} = 260 M^{-1}$) and β - ($K_{1:1} = 1600 M^{-1}$, and $K_{1:2} = 370 M^{-1}$) cyclodextrin complexes were obtained.

The β -cyclodextrin system deposited a crystalline complex of I- β -cyclodextrin (1:2) at high β -cyclodextrin concentrations. Stoichiometry based on the data in the plateau region (13) in Fig. 1 was in good agreement with that obtained by isolation and analysis of the crystalline complex. In sharp contrast, the α -cyclodextrin system did not give any solid complex, a smaller cavity size apparently allowing little penetration of the bulky guest molecule.

The dissolution behavior and chemical stability of the isolated β -cyclodextrin complex were examined. The dissolution rate of the complex

in powder was extremely large compared with that of I in water (Fig. 2), indicating an improved bioavailability. As shown in Table I, the decomposition of I was significantly retarded by inclusion complex formation. Thus, the increased dissolution rate, together with improved chemical stability, suggested that the β -cyclodextrin-I complex may have great utility in the development of fast dissolving dosage forms with prolonged storage time.

Furthermore, thermal gravimetric analysis⁶ showed that the volatility of I was extremely depressed by binding to β -cyclodextrin. The crystallinity of the complex should facilitate drug formulation, which is difficult with uncomplexed I because it occurs as a viscous oil.

REFERENCES

- (1) "The Prostaglandins: Clinical Application in Human Reproduction," E. M. Southern, Ed., Futura Publishing, Mount Kisco, N.Y., 1972.
- (2) S. Takagi, H. Sakata, T. Yoshida, S. Nakazawa, T. K. Fujita, Y. Tomida, K. Itoh, and R. Matsukawa, *Prostaglandins*, 14, 791 (1977).
- (3) S. Takagi, H. Sakata, T. Yoshida, K. Den, T. K. Fujita, H. Amemiya, and M. Tomita, *ibid.*, 15, 913 (1978).
- (4) J. L. Lach and J. Cohen, *J. Pharm. Sci.*, 52, 137 (1963).
- (5) A. L. Thakkar, P. B. Kuehn, J. H. Perrin, and W. L. Wilham, *ibid.*, 61, 1841 (1972).
- (6) M. Otagiri, J. H. Perrin, K. Uekama, K. Ikeda, and K. Takeo, *Pharm. Acta Helv.*, 51, 343 (1976).
- (7) Y. Hamada, N. Nambu, and T. Nagai, *Chem. Pharm. Bull.*, 23, 1205 (1975).
- (8) K. H. Frömring and I. Weyerman, *Arzneim.-Forsch.*, 23, 424 (1973).
- (9) K. Uekama, F. Hirayama, K. Ikeda, and K. Inaba, *J. Pharm. Sci.*, 66, 706 (1977).
- (10) K. Uekama, F. Hirayama, S. Yamasaki, M. Otagiri, and K. Ikeda, *Chem. Lett.*, 1977, 679.
- (11) K. Uekama and F. Hirayama, *Chem. Pharm. Bull.*, 26, 1195 (1978).
- (12) H. Nogami, T. Nagai, and T. Yotsuyanagi, *ibid.*, 17, 499 (1969).
- (13) T. Higuchi and K. A. Connors, *Adv. Anal. Chem. Instr.*, 4, 117 (1965).
- (14) T. Higuchi and H. Kristiansen, *J. Pharm. Sci.*, 58, 661 (1969).

ACKNOWLEDGMENTS

Supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan.

⁶ Model DT-20B thermal analyzer, Shimadzu, Osaka, Japan.